Differential isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 mutation-related landscape in intrahepatic cholangiocarcinoma

The Oncologist, Journal Year: 2024, Volume and Issue: unknown

Published: June 6, 2024

Abstract Background Patients with intrahepatic cholangiocarcinoma (ICC) are prone to recurrence and poor survival. Targeted therapy related isocitrate dehydrogenase (IDH) is an extremely important treatment. IDH1 IDH2 mutations generally thought have similar effects on the tumor landscape. However, it doubtful whether these 2 exactly same cells microenvironment. Methods All collected samples were subjected simultaneous whole-exon sequencing proteome sequencing. Results accounted for 12.2%, 5.5%, all missense mutations. Tumors IDH had lower proportions of KRAS TP53 Mutated genes obviously enriched in kinase pathway tumors The signaling pathways mainly activation cellular metabolic activities increase inhibitory immune Moreover, unique enrichment DNA repair mutants secretion biological molecules mutants. Inhibitory might be more prominent mutants, expression checkpoints PVR HLA-DQB1 was metabolism-related inflammation-immune response clusters, some belonged replication cluster. Conclusions These results revealed differential mutation-related landscapes, we provided reference database guide ICC

Language: Английский

---

Targeted Therapy with Polymeric Nanoparticles in PBRM1-Mutant Biliary Tract Cancers: Harnessing DNA Damage Repair Mechanisms

Critical Reviews in Oncology/Hematology, Journal Year: 2024, Volume and Issue: 204, P. 104505 - 104505

Published: Sept. 8, 2024

Language: Английский

---

Effectiveness, safety, and biomarker analysis of lenvatinib plus toripalimab as chemo-free therapy in advanced intrahepatic cholangiocarcinoma: a real-world study

Cancer Immunology Immunotherapy, Journal Year: 2024, Volume and Issue: 73(12)

Published: Oct. 3, 2024

Language: Английский

---

Advances in target drugs and immunotherapy for biliary tract cancer

Expert Review of Gastroenterology & Hepatology, Journal Year: 2024, Volume and Issue: 18(10), P. 605 - 630

Published: Oct. 2, 2024

Introduction After years of treatment stagnation in biliary tract cancers (BTC), there has been a notable shift with the emergence targeted therapies and immunotherapy, leading to substantial progress tackling this aggressive disease.

Language: Английский

---

Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis

Journal of Personalized Medicine, Journal Year: 2022, Volume and Issue: 12(8), P. 1247 - 1247

Published: July 29, 2022

Recent years have witnessed the advent of molecular profiling for intrahepatic cholangiocarcinoma (iCCA), and new techniques led to identification several alterations. Precision oncology approaches been widely evaluated are currently under assessment, as shown by recent development a wide range agents targeting Fibroblast Growth Factor Receptor (FGFR) 2, Isocitrate Dehydrogenase 1 (IDH-1), BRAF. However, knowledge gaps persist in understanding genomic landscape this hepatobiliary malignancy.In current study, we aimed comprehensively analyze clinicopathological features BAP1-mutated iCCA patients public datasets increase on biological profile iCCA.The database including 772 iCCAs, identified BAP1 mutations 120 cases (15.7%). According our analysis, no differences terms overall survival relapse-free were observed between wild-type receiving radical surgery. In addition, IDH1, PBRM1, ARID1A most commonly co-altered genes iCCAs.The characterization is destined become increasingly important, more efforts implement genomics analysis warranted.

Language: Английский

---